Research article

Pick analysis

History arrow_forward
Steam rising off the water at a lake in Central Otago, New Zealand
Research brief

Nov 19, 2026 Afternoon

05:20 PM UTC
Regeneron Pharmaceuticals, Inc. REGN medium
Conf. Medium
Pick Pr. $936.03
Stop Level $888.00
Curr. Pr. $927.73
Change -0.89%
Rem. Days 7

Summary

  • Recommendation (Momentum — Defensive Post-FDA Approval): Buy Regeneron Pharmaceuticals, Inc. (REGN), a verified S&P 500 constituent (verified_at: 2026-11-19 12:22:45 EST en.wikipedia.S&P 500 constituent snapshotMembership fetched at 2026-11-19T17:22:45.394283+00:00Visit original website ↗) with zero overlap against active public positions. The decider's synchronized research quote is $937.940 (observed 2026-11-19 13:02:00 EST finance.yahooYahoo Finance: Regeneron Pharmaceuticals, Inc.Yahoo Finance quote pageVisit original website ↗); a fresh publication quote check confirms $936.031 at 2026-11-19 13:17:00 EST (+0.15% above regular-session VWAP $934.585, with 12/12 recent 5-minute bars closing above VWAP finance.yahooYahoo Finance: Regeneron Pharmaceuticals, Inc.Yahoo Finance quote pageVisit original website ↗), leaving the thesis and structural stop intact.
  • Core Thesis: On 2026-11-18 at 18:03 EST, the FDA approved Regeneron's Livsayis (cemdisiran), the first and only quarterly subcutaneous siRNA therapy for anti-AChR+ generalized myasthenia gravis (gMG) investor.regeLivsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing | Regeneron Pharmaceuticals Inc.Skip to Content Regeneron.com Contact Us Open Search Bar NEWS EVENTS & PRESENTATIONS STOCK INFORMATION FINANCIALS GOVERNANCE RESOURCES News / Press Releases / Livsayis™ (Cemdisiran) Approved By The FDA As First And Only SiRNA Therapy In Generalized Myasthenia Gravis And Only Treatment With Four-Times-A-Year Subcutaneous Dosing RELEASE DETAILS Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy…Visit original website ↗. In a risk-off market (SPY below its 200-day SMA, VIX near 28, 10Y Treasury yield at 5.06% finance.yahooYahoo Finance: State Street SPDR S&P 500 ETF TrustYahoo Finance quote pageVisit original website ↗, finance.yahooYahoo Finance: CBOE Volatility IndexYahoo Finance quote pageVisit original website ↗, finance.yahooYahoo Finance: CBOE Interest Rate 10 Year T NoteYahoo Finance quote pageVisit original website ↗), REGN combines a fresh regulatory catalyst, 0.095 beta, 13.19x forward P/E (at the research quote; 13.16x at publication), $16.2B net cash mfn.seRegeneron Reports Third Quarter 2026 Financial and ...X-dag kvartalsutdelning REGN 0.94. 2026-10-30, -, Kvartalsrapport 2026 ... Regeneron's website at www.regeneron.com. Upon registration ...Visit original website ↗, +19.86% 20-day relative strength vs. SPY, and clean above-VWAP intraday acceptance finance.yahooYahoo Finance: Regeneron Pharmaceuticals, Inc.Yahoo Finance quote pageVisit original website ↗.
  • Key Projections (Decider Estimates, 7-Calendar-Day Horizon): Under the decider's authored scenario anchored at $937.940, REGN carries a reference 7-day target (T1) of $988.00 (+5.34%), an actual 1.8x full-position profit barrier of $1,028.05 (+9.61%), an authored structural stop at $888.00 (-5.32%), and a conditional expected stop exit of $874.00 (-6.82% before 0.15% friction). Using uncalibrated decider exit probabilities (18% barrier / 18% stop / 64% time exit at +1.61%), the decider estimates a base net expected return of +1.38% (+1.10% expected excess over the decider's +0.28% SPY benchmark) and an uncertainty-adjusted net excess return of -2.25% (with 3.35% declared uncertainty covering adverse stress). A verified $0.94/share (+0.10%) ex-dividend tomorrow (2026-11-20) finance.yahooRegeneron Pharmaceuticals, Inc. (REGN) Stock Historical Prices & Data - Yahoo FinanceSkip to navigation Skip to main content Skip to right column Home News Finance Sports More Sign in My Portfolio Markets Anthropic IPO News Research & Tools Personal Finance Watch Crypto AI Network AlphaSpace Get Finance Plus US Markets S&P 500 7,218.98 -104.65 -1.43% Dow 30 49,331.06 -867.11 -1.73% Nasdaq 24,068.04 -361.84 -1.48% Russell 2000 2,679.52 -34.79 -1.28% 10-Yr Bond 5.06 -0.00 -0.04% VIX 26.87 +2.31 +9.42%…Visit original website ↗, stockanalysisRegeneron Pharmaceuticals (REGN) Dividend History, Dates & YieldSkip to main content / Ask AI Help Log In Sign Up 🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans Claim Offer Home Watchlist Stocks Stock Screener Stock Exchanges By Country Comparison Tool Earnings Calendar Earnings CallsNew By Industry Stock Lists Top Stocks Corporate Actions IPOs ETFs Analysts News Trending Private Companies Technical Chart Fundamental Chart Market Movers Market Newsletter Stock…Visit original website ↗ is excluded from price-barrier math and provides a separate cash cushion.
  • Confidence Rationale (Medium, Descriptive Only): Confidence is calibrated to Medium because REGN ranks #1 across all ten reviewed S&P 500 finalists on base net expected return, uncertainty-adjusted excess return, beta, and intraday VWAP structure, while explicitly accounting for muted post-approval relative volume (0.52x pace RV), Livsayis's meningococcal boxed warning and REMS requirement regeneronLIVSAYIS™ Full Prescribing Information1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LIVSAYIS safely and effectively. See full prescribing information for LIVSAYIS. LIVSAYIS™ (cemdisiran) injection, for subcutaneous use Initial U.S. Approval: 2026 WARNING: SERIOUS MENINGOCOCCAL INFECTIONS See full prescribing information for complete boxed warning. LIVSAYIS increases the risk of serious and…Visit original website ↗, Healthcare sector crowding (16.56%), and Thanksgiving-week macro/liquidity risk nyseHolidays & Trading HoursICE NYSE LOGIN Listings Trading Market Data Insights About Trading at NYSE / Holidays & Trading Hours Holidays & Trading Hours All NYSE markets observe U.S. holidays as listed below for 2026, 2027, and 2028. Trading Days Trading Hours Holiday 2026 2027 2028 New Year’s Day Thursday, January 1 Friday, January 1 —* Martin Luther King, Jr. Day Monday, January 19 Monday, January 18 Monday, January 17 Washington's…Visit original website ↗, bea.govRelease Schedule | U.S. Bureau of Economic Analysis (BEA)2026 Release November 20 8:30 AM News Activities of U.S. Multinational Enterprises, 2024 November 25 8:30 AM News GDP (Second Estimate) and Corporate Profits, ...Visit original website ↗.

Why Now

  • Fresh Regulatory Catalyst (First Full Trading Session): After the close on 2026-11-18 (18:03 EST), Regeneron announced FDA approval of Livsayis (cemdisiran) for adults with anti-AChR antibody-positive generalized myasthenia gravis (gMG) investor.regeLivsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing | Regeneron Pharmaceuticals Inc.Skip to Content Regeneron.com Contact Us Open Search Bar NEWS EVENTS & PRESENTATIONS STOCK INFORMATION FINANCIALS GOVERNANCE RESOURCES News / Press Releases / Livsayis™ (Cemdisiran) Approved By The FDA As First And Only SiRNA Therapy In Generalized Myasthenia Gravis And Only Treatment With Four-Times-A-Year Subcutaneous Dosing RELEASE DETAILS Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy…Visit original website ↗, reutersUS FDA approves Regeneron's drug for generalized ...The drug, cemdisiran, branded as Livsayis, was approved for adults with generalized myasthenia gravis who test positive for anti ...Visit original website ↗. Today (2026-11-19) is the first regular session for institutional price discovery. Regeneron holds worldwide commercial rights investor.regeLivsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing | Regeneron Pharmaceuticals Inc.Skip to Content Regeneron.com Contact Us Open Search Bar NEWS EVENTS & PRESENTATIONS STOCK INFORMATION FINANCIALS GOVERNANCE RESOURCES News / Press Releases / Livsayis™ (Cemdisiran) Approved By The FDA As First And Only SiRNA Therapy In Generalized Myasthenia Gravis And Only Treatment With Four-Times-A-Year Subcutaneous Dosing RELEASE DETAILS Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy…Visit original website ↗, paying licensor Alnylam a $25M approval milestone plus tiered double-digit royalties up to 15% on global net sales investors.alAlnylam Collaborator Regeneron Secures FDA Approval of Livsayis™ (cemdisiran), the Seventh FDA-Approved Ther | AlnylamSkip to main content Investors Medical Professionals Patients Careers Quick Links Follow Us Our Company Our Science Our Products Our News Alnylam Collaborator Regeneron Secures FDA Approval of Livsayis™ (cemdisiran), the Seventh FDA-Approved Therapeutic from Alnylam's RNAi Platform in Less Than Nine Years Nov 19, 2026 − First RNAi Therapeutic Approved for Generalized Myasthenia Gravis – − Alnylam to Receive $25…Visit original website ↗. Quarterly (4x/year) subcutaneous dosing offers a notable convenience differentiation against Argenx's Vyvgart and AstraZeneca's Ultomiris investor.regeLivsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing | Regeneron Pharmaceuticals Inc.Skip to Content Regeneron.com Contact Us Open Search Bar NEWS EVENTS & PRESENTATIONS STOCK INFORMATION FINANCIALS GOVERNANCE RESOURCES News / Press Releases / Livsayis™ (Cemdisiran) Approved By The FDA As First And Only SiRNA Therapy In Generalized Myasthenia Gravis And Only Treatment With Four-Times-A-Year Subcutaneous Dosing RELEASE DETAILS Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy…Visit original website ↗.
  • Operating Momentum & Fortress Valuation: The approval reinforces strong underlying execution following Regeneron's Q3 2026 earnings release on 2026-10-30 ($5.1B revenue +36% YoY, $20.07 non-GAAP EPS, and $16.2B net cash mfn.seRegeneron Reports Third Quarter 2026 Financial and ...X-dag kvartalsutdelning REGN 0.94. 2026-10-30, -, Kvartalsrapport 2026 ... Regeneron's website at www.regeneron.com. Upon registration ...Visit original website ↗). At $937.940 (13:02:00 EST research quote; $936.031 at 13:17:00 EST publication check), REGN trades at 13.19x forward P/E (13.16x at publication) and 1.15x PEG finance.yahooYahoo Finance: Regeneron Pharmaceuticals, Inc.Yahoo Finance quote pageVisit original website ↗—a sharp discount to defensive peers such as WMT (39.06x forward P/E).
  • Price Momentum & Clean Entry Context: Over the 20 completed sessions through 2026-11-18, REGN gained +15.44%, outperforming XLV by +15.51% and SPY by +19.86% finance.yahooYahoo Finance: Regeneron Pharmaceuticals, Inc.Yahoo Finance quote pageVisit original website ↗. Because today's intraday move (-0.80% at 13:02 EST; -1.00% at 13:17 EST) is well within normal daily range (ATR14 $40.044 or 4.27%), the post-catalyst over-extension gate is not triggered. Crucially, REGN is holding cleanly above regular-session VWAP (+0.37% above $934.469 at 13:02 EST; +0.15% above $934.585 at 13:17 EST, with 12/12 recent 5-minute bars closing above VWAP finance.yahooYahoo Finance: Regeneron Pharmaceuticals, Inc.Yahoo Finance quote pageVisit original website ↗) on clean volume data.
  • Why Risk/Reward Beats Rejected Finalists: Across the 10-candidate final gate, REGN (#1) outperforms all viable alternates on decider-estimated base net return (+1.38%), uncertainty-adjusted net excess return (-2.25% price-only; ~-2.15% including the Nov 20 dividend), and beta (0.095):
    • vs. WMT (#2, $126.100): WMT posted a fresh Q3 FY27 beat/raise and holds above reconciled clean VWAP ($125.080–$125.119), but trails REGN on base net return (+0.60% vs. +1.38%), uncertainty-adjusted excess (-2.43% vs. -2.25%), valuation (39.06x vs. 13.19x forward P/E), and intraday volume-feed integrity.
    • vs. NRG (#3, $94.435) & FDXF (#4, $127.315): Both offer better portfolio sector diversification (0.00% Utilities and 8.39% Industrials), but neither has a fresh Nov 18–19 catalyst, both trade below regular-session VWAP (0/12 bars above VWAP finance.yahoYahoo Finance: NRG Energy, Inc.Yahoo Finance quote pageVisit original website ↗, finance.yahoYahoo Finance: FedEx Freight Holding Company, Inc.Yahoo Finance quote pageVisit original website ↗), and FDXF faces a Nov 3 Raymond James PT cut ($165 → $162 marketscreenRaymond James Adjusts Price Target on FedEx Freight Holding to $162 From $165 | MarketScreenerEvery day, we give you free access to essential global business and financial news, through the work of our journalists and our partnerships with leading news and data providers. Access our content for free by accepting the use of cookies. To access our free content, you must agree to the use of your personal data to personalize ads and content, analyze our audience, and develop our products and services…Visit original website ↗, streetinsideFedEx Freight (FDXF) PT Lowered to $162 at Raymond JamesClose (X) Set up related e-mail alerts – FREE! Categories Entities Stocks Sign up! Analyst Comments Analyst PT Change Raymond James ($$) Maynard Um ($$) Mark Zuckerberg ARK ($$) FDXF E-mail Address Log-In | Home | E-mail Alerts | My Headlines | Portfolio JOIN SI Premium Calendars Ratings Mergers Earnings Dividends IPOs Hedge Funds Premium Letters Send a Tip API/Data QUICK LINKS : Goldman Sachs Conviction Buy List…Visit original website ↗) plus FedEx's SEC-verified 19.9% retained stake overhang sec.govfdx-20260531FedEx retained 19.9% of the outstanding shares of FedEx Freight common stock. ... TSA”), an agency within the Department of Homeland Security, has ...Visit original website ↗, materials.prMay 13, 2026 Dear FedEx Corporation StockholderFedEx will retain a 19.9% stake in FedEx Freight in order to increase financial flexibility and support ... “FDXF.” I encourage you to read ...Read more 244 pagesVisit original website ↗.
    • vs. CRWD (#5, $246.000) & TTWO (#6, $213.815): CRWD is fading -2.07% below VWAP on zero fresh issuer catalyst at 152.7x forward P/E ahead of Dec 1 earnings ir.crowdstriCrowdStrike Announces Date of Fiscal Third Quarter 2027 ...it will release financial results for its fiscal third quarter 2027 ended October 31, 2026 after the U.S. market close on Tuesday, December 1, ...Visit original website ↗, finance.yahoYahoo Finance: CrowdStrike Holdings, Inc.Yahoo Finance quote pageVisit original website ↗; TTWO is fading -0.92% below VWAP on GTA VI launch day with 6.07% ATR14 and 4.90% stress uncertainty finance.yahoYahoo Finance: Take-Two Interactive Software, Inc.Yahoo Finance quote pageVisit original website ↗.

Business And Market Context

  • Broad Market Regime (Risk-Off Pullback, Not Confirmed Crash): At the decider's 13:02:00 EST snapshot, SPY traded at $722.825 (-1.01% 1D, -7.52% off its 52-week high, intraday below its $730.024 200-day SMA finance.yahooYahoo Finance: State Street SPDR S&P 500 ETF TrustYahoo Finance quote pageVisit original website ↗), ^VIX stood at 28.070 finance.yahooYahoo Finance: CBOE Volatility IndexYahoo Finance quote pageVisit original website ↗, and the 10-year Treasury yield sat at 5.060% finance.yahooYahoo Finance: CBOE Interest Rate 10 Year T NoteYahoo Finance quote pageVisit original website ↗. Equities are digesting an AI/tech unwind, tighter U.S. restrictions on Chinese AI computing roic.aiVIX Spikes to Two-Week High as Tech Selloff and AI Chip ...The spike comes as investors grapple with a technology-led selloff, tighter U.S. restrictions on Chinese access to advanced AI computing, and ...Visit original website ↗, sticky prior inflation (3.6% YoY PCE / 3.1% Core PCE marketwatchU.S. Economic CalendarU.S. Economic CalendarMajor U.S. Economic Reports & Fed Speakers for 11/16 - 11/27 ; 8:30 AM, Weekly Jobless Claims ; Add to My Calendar. Jobless Claims. PERIOD ...Visit original website ↗), and soft Nov 19 Philadelphia Fed (6.3) and Leading Indicators (-0.3%) prints marketwatchU.S. Economic CalendarU.S. Economic CalendarMajor U.S. Economic Reports & Fed Speakers for 11/16 - 11/27 ; 8:30 AM, Weekly Jobless Claims ; Add to My Calendar. Jobless Claims. PERIOD ...Visit original website ↗. Because 5 of 11 sectors remain above their 200-day SMAs, this is a high-volatility pullback rather than a confirmed bear-market crash, favoring low-beta (0.095), self-funded leaders like REGN.
  • Thanksgiving-Week Holding Window & Exchange Calendar: The authoritative 7-calendar-day (168-hour) hold runs from 2026-11-19 12:20:01 EST to 2026-11-26 12:20:01 EST. Per the official NYSE holiday calendar nyseHolidays & Trading HoursICE NYSE LOGIN Listings Trading Market Data Insights About Trading at NYSE / Holidays & Trading Hours Holidays & Trading Hours All NYSE markets observe U.S. holidays as listed below for 2026, 2027, and 2028. Trading Days Trading Hours Holiday 2026 2027 2028 New Year’s Day Thursday, January 1 Friday, January 1 —* Martin Luther King, Jr. Day Monday, January 19 Monday, January 18 Monday, January 17 Washington's…Visit original website ↗, U.S. equity markets are closed on Thursday, November 26, 2026 (Thanksgiving Day) and close early at 1:00 p.m. EST on Friday, November 27, 2026. Accordingly, the first liquid regular-session exit window after maturity is Friday, 2026-11-27 09:30–13:00 EST (~4.5–5.0 effective regular trading sessions).
  • Scheduled Macro Catalysts Inside the Window: Major publisher-verified U.S. macro releases cluster on Monday, Nov 23 (9:45 AM EST S&P Global Flash US PMI pmi.spglobalPMI Calendar - pmi.spglobal.comThe standard monthly release schedules for S&P Global PMI surveys. Calendar Upcoming 2026 November 22 22:00. Global Flash US PMI November 24 00:30 UTCSPVisit original website ↗), Tuesday, Nov 24 (10:00 AM EST Conference Board Consumer Confidence conference-bUS Consumer ConfidenceThe Conference Board Consumer Confidence Index® rose by 7.5 points to 91.7 (1985=100) in October, up from 84.2 in September (a slight upward revision).Visit original website ↗), and especially Wednesday, Nov 25 (8:30 AM EST BEA Q3 GDP second estimate & Oct PCE/Core PCE bea.govRelease Schedule | U.S. Bureau of Economic Analysis (BEA)2026 Release November 20 8:30 AM News Activities of U.S. Multinational Enterprises, 2024 November 25 8:30 AM News GDP (Second Estimate) and Corporate Profits, ...Visit original website ↗, Census Oct Advance Durable Goods census.govEconomic Indicator Release Schedule: List View2026 Economic Indicator Calendar. Advance Report on Durable Goods--Manufacturers' Shipments, Inventories, and Orders 8:30 AM November 2026Visit original website ↗, census.govMONTHLY FULL REPORT ON MANUFACTURERS' ...The Advance Report on durable goods for October is scheduled for release on November 25, 2026, at 8:30 a.m. EST and the Full Report on December ... 12 pagesVisit original website ↗, shifted Initial Jobless Claims marketwatchU.S. Economic CalendarU.S. Economic CalendarMajor U.S. Economic Reports & Fed Speakers for 11/16 - 11/27 ; 8:30 AM, Weekly Jobless Claims ; Add to My Calendar. Jobless Claims. PERIOD ...Visit original website ↗; 10:00 AM EST New Residential Sales census.govEconomic Indicator Release Schedule: List View2026 Economic Indicator Calendar. Advance Report on Durable Goods--Manufacturers' Shipments, Inventories, and Orders 8:30 AM November 2026Visit original website ↗; 2:00 PM EST Federal Reserve Beige Book federalreserFederal Reserve Board - Calendar: November 2026FOMC Meetings. Time: Release Date(s):. 2:00 p.m.. FOMC Minutes. Meeting of October 27-28. 18. Beige Book. Time: Release Date(s):. 2:00 p.m..Visit original website ↗).
  • Company-Specific Calendar: REGN has no pending company-specific binary events (earnings, FDA/PDUFA, or court rulings) between 2026-11-19 and 2026-11-27. Its quarterly $0.94/share cash dividend goes ex-dividend tomorrow, 2026-11-20 (payable 2026-12-03) finance.yahooRegeneron Pharmaceuticals, Inc. (REGN) Stock Historical Prices & Data - Yahoo FinanceSkip to navigation Skip to main content Skip to right column Home News Finance Sports More Sign in My Portfolio Markets Anthropic IPO News Research & Tools Personal Finance Watch Crypto AI Network AlphaSpace Get Finance Plus US Markets S&P 500 7,218.98 -104.65 -1.43% Dow 30 49,331.06 -867.11 -1.73% Nasdaq 24,068.04 -361.84 -1.48% Russell 2000 2,679.52 -34.79 -1.28% 10-Yr Bond 5.06 -0.00 -0.04% VIX 26.87 +2.31 +9.42%…Visit original website ↗, stockanalysisRegeneron Pharmaceuticals (REGN) Dividend History, Dates & YieldSkip to main content / Ask AI Help Log In Sign Up 🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans Claim Offer Home Watchlist Stocks Stock Screener Stock Exchanges By Country Comparison Tool Earnings Calendar Earnings CallsNew By Industry Stock Lists Top Stocks Corporate Actions IPOs ETFs Analysts News Trending Private Companies Technical Chart Fundamental Chart Market Movers Market Newsletter Stock…Visit original website ↗, reutersRegeneron Pharmaceuticals, Inc. (REGN.DE)Regeneron Pharmaceuticals, Inc. View Story. Currency (Primary listing). USD ... 0.94 USD. Previous Ex-Date. Nov 20, 2026. Previous Payment Date. Dec 3, 2026.Visit original website ↗; shares will mechanically open ~$0.94 lower tomorrow while entitling today's buyer to $0.94 cash.

Factor Stack

Factor Rating Supporting Evidence & Decider Assessment
Catalyst / News Edge Strong Fresh 2026-11-18 18:03 EST FDA approval of Livsayis (first quarterly subcutaneous siRNA for anti-AChR+ gMG, worldwide commercial rights) investor.regeLivsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing | Regeneron Pharmaceuticals Inc.Skip to Content Regeneron.com Contact Us Open Search Bar NEWS EVENTS & PRESENTATIONS STOCK INFORMATION FINANCIALS GOVERNANCE RESOURCES News / Press Releases / Livsayis™ (Cemdisiran) Approved By The FDA As First And Only SiRNA Therapy In Generalized Myasthenia Gravis And Only Treatment With Four-Times-A-Year Subcutaneous Dosing RELEASE DETAILS Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy…Visit original website ↗, investors.alAlnylam Collaborator Regeneron Secures FDA Approval of Livsayis™ (cemdisiran), the Seventh FDA-Approved Ther | AlnylamSkip to main content Investors Medical Professionals Patients Careers Quick Links Follow Us Our Company Our Science Our Products Our News Alnylam Collaborator Regeneron Secures FDA Approval of Livsayis™ (cemdisiran), the Seventh FDA-Approved Therapeutic from Alnylam's RNAi Platform in Less Than Nine Years Nov 19, 2026 − First RNAi Therapeutic Approved for Generalized Myasthenia Gravis – − Alnylam to Receive $25…Visit original website ↗. Balanced by boxed warning/REMS and incremental near-term revenue scale vs. $96.8B market cap regeneronLIVSAYIS™ Full Prescribing Information1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LIVSAYIS safely and effectively. See full prescribing information for LIVSAYIS. LIVSAYIS™ (cemdisiran) injection, for subcutaneous use Initial U.S. Approval: 2026 WARNING: SERIOUS MENINGOCOCCAL INFECTIONS See full prescribing information for complete boxed warning. LIVSAYIS increases the risk of serious and…Visit original website ↗, finance.yahooYahoo Finance: Regeneron Pharmaceuticals, Inc.Yahoo Finance quote pageVisit original website ↗.
Growth & Profitability Strong Q3 2026 revenue grew +36% YoY to $5.1B with $20.07 non-GAAP EPS and $16.2B net cash mfn.seRegeneron Reports Third Quarter 2026 Financial and ...X-dag kvartalsutdelning REGN 0.94. 2026-10-30, -, Kvartalsrapport 2026 ... Regeneron's website at www.regeneron.com. Upon registration ...Visit original website ↗. Self-funded R&D engine with no rate-sensitivity refinancing risk.
Valuation Attractive 13.19x forward P/E at the $937.940 research quote (13.16x at $936.031 publication quote), 20.69x trailing P/E, 1.15x PEG, and 2.80x P/B finance.yahooYahoo Finance: Regeneron Pharmaceuticals, Inc.Yahoo Finance quote pageVisit original website ↗—compelling defensive value relative to WMT (39.06x) and CRWD (152.7x).
Momentum / Relative Strength Strong +15.44% 20-day return, +19.86% 20-day cumulative outperformance vs. SPY, trading well above rising SMA20 ($901.906), SMA50 ($824.372), SMA200 ($748.885), and VWAP20 ($912.963) finance.yahooYahoo Finance: Regeneron Pharmaceuticals, Inc.Yahoo Finance quote pageVisit original website ↗. Clean intraday acceptance above regular VWAP (12/12 recent 5m bars at 13:17 EST finance.yahooYahoo Finance: Regeneron Pharmaceuticals, Inc.Yahoo Finance quote pageVisit original website ↗).
Sentiment / Social Confirmation Constructive / Uncrowded Broad biotech/pharma media coverage (reutersUS FDA approves Regeneron's drug for generalized ...The drug, cemdisiran, branded as Livsayis, was approved for adults with generalized myasthenia gravis who test positive for anti ...Visit original website ↗, biospaceRegeneron racks up another first as FDA greenlights ...Late Wednesday evening, the FDA greenlit cemdisiran—to be marketed as Livsayis—for adults with gMG who are positive for anti-acetylcholine ...Visit original website ↗, mda.orgFDA Approves Livsayis™ (cemdisiran) for Adults Living ...... Regeneron Pharmaceuticals, for the treatment of adults living with ... “The FDA's approval of Livsayis™ (cemdisiran) marks yet another ...Visit original website ↗) and constructive retail discussion without speculative crowding (2.27% short interest finance.yahooYahoo Finance: Regeneron Pharmaceuticals, Inc.Yahoo Finance quote pageVisit original website ↗).
EPS Revisions / Estimate Context Supportive (Qualitative) Q3 2026 beat ($20.07 non-GAAP EPS mfn.seRegeneron Reports Third Quarter 2026 Financial and ...X-dag kvartalsutdelning REGN 0.94. 2026-10-30, -, Kvartalsrapport 2026 ... Regeneron's website at www.regeneron.com. Upon registration ...Visit original website ↗) and Livsayis approval support multi-year pipeline durability; specific post-approval consensus EPS revision counts were not freshly published within the 19 hours since approval.

Investment Thesis

REGN is the highest-conviction 7-calendar-day long in the S&P 500 on 2026-11-19 because it pairs an idiosyncratic, newly approved commercial asset (Livsayis investor.regeLivsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing | Regeneron Pharmaceuticals Inc.Skip to Content Regeneron.com Contact Us Open Search Bar NEWS EVENTS & PRESENTATIONS STOCK INFORMATION FINANCIALS GOVERNANCE RESOURCES News / Press Releases / Livsayis™ (Cemdisiran) Approved By The FDA As First And Only SiRNA Therapy In Generalized Myasthenia Gravis And Only Treatment With Four-Times-A-Year Subcutaneous Dosing RELEASE DETAILS Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy…Visit original website ↗) with defensive institutional sponsorship (0.095 beta, 13.19x forward P/E, $16.2B net cash finance.yahooYahoo Finance: Regeneron Pharmaceuticals, Inc.Yahoo Finance quote pageVisit original website ↗, mfn.seRegeneron Reports Third Quarter 2026 Financial and ...X-dag kvartalsutdelning REGN 0.94. 2026-10-30, -, Kvartalsrapport 2026 ... Regeneron's website at www.regeneron.com. Upon registration ...Visit original website ↗) during a high-volatility macro pullback. While higher-beta technology and sympathy trades (CRWD, TTWO, MPWR, AVGO) are failing below intraday VWAP under 5.06% 10-year yields and VIX 28, REGN is holding cleanly above regular-session VWAP ($934.469 at 13:02 EST; $934.585 at 13:17 EST finance.yahooYahoo Finance: Regeneron Pharmaceuticals, Inc.Yahoo Finance quote pageVisit original website ↗) with structural support stacked beneath it (VWAP20 $912.963, SMA20 $901.906).

In the decider's execution-aware scenario anchored at $937.940, REGN is not a bet on an explosive breakout—the 1.8x full-position profit barrier at $1,028.05 (+9.61%, above the $991.73 52-week high) is assigned a conservative 18% probability. Instead, the primary edge comes from asymmetric defensive drift (64% time-exit probability at +1.61% to $953.07) plus a wide, structurally protected stop ($888.00, -5.32%), generating a decider-estimated +1.38% net expected return (+1.10% excess over SPY's +0.28% benchmark, before the separate +$0.94 Nov 20 dividend cushion).

Risks And Thesis Breakers

  • Company & Commercial Risk (Livsayis Label / EYLEA Competition): Regeneron's official Full Prescribing Information PDF confirms Livsayis carries a Boxed Warning for serious, life-threatening meningococcal infections (requiring vaccination against serogroups A, C, W, Y, and B at least 2 weeks prior to first dose) and is restricted exclusively to the LIVSAYIS REMS program regeneronLIVSAYIS™ Full Prescribing Information1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LIVSAYIS safely and effectively. See full prescribing information for LIVSAYIS. LIVSAYIS™ (cemdisiran) injection, for subcutaneous use Initial U.S. Approval: 2026 WARNING: SERIOUS MENINGOCOCCAL INFECTIONS See full prescribing information for complete boxed warning. LIVSAYIS increases the risk of serious and…Visit original website ↗, investor.regeLivsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing | Regeneron Pharmaceuticals Inc.Skip to Content Regeneron.com Contact Us Open Search Bar NEWS EVENTS & PRESENTATIONS STOCK INFORMATION FINANCIALS GOVERNANCE RESOURCES News / Press Releases / Livsayis™ (Cemdisiran) Approved By The FDA As First And Only SiRNA Therapy In Generalized Myasthenia Gravis And Only Treatment With Four-Times-A-Year Subcutaneous Dosing RELEASE DETAILS Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy…Visit original website ↗—an adoption friction that rival FcRn inhibitor Vyvgart does not face zacksREGN Gets FDA Nod for Livsayis in Generalized Myasthenia Gravis - November 19, 2026 - Zacks.comSkip to main content X We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use…Visit original website ↗. Ongoing biosimilar erosion in legacy 2mg EYLEA remains a structural overhang.
  • Entry, Volume & Overextension Risk: Post-approval intraday pace relative volume is muted (0.52x at the research check), and REGN already rallied +15.44% over the prior 20 sessions finance.yahooYahoo Finance: Regeneron Pharmaceuticals, Inc.Yahoo Finance quote pageVisit original website ↗. Muted volume indicates the approval was partly anticipated and limits immediate breakout momentum.
  • Market, Macro & Liquidity Risk: A hot Wednesday, Nov 25 8:30 AM EST Oct PCE/Core PCE print bea.govRelease Schedule | U.S. Bureau of Economic Analysis (BEA)2026 Release November 20 8:30 AM News Activities of U.S. Multinational Enterprises, 2024 November 25 8:30 AM News GDP (Second Estimate) and Corporate Profits, ...Visit original website ↗ could push 10-year yields above 5.20% and trigger broad risk-off liquidation into compressed Thanksgiving-week liquidity (NYSE closed Nov 26; 1:00 PM EST early close Nov 27 nyseHolidays & Trading HoursICE NYSE LOGIN Listings Trading Market Data Insights About Trading at NYSE / Holidays & Trading Hours Holidays & Trading Hours All NYSE markets observe U.S. holidays as listed below for 2026, 2027, and 2028. Trading Days Trading Hours Holiday 2026 2027 2028 New Year’s Day Thursday, January 1 Friday, January 1 —* Martin Luther King, Jr. Day Monday, January 19 Monday, January 18 Monday, January 17 Washington's…Visit original website ↗).
  • Portfolio Crowding & Valuation Risk: Healthcare is already 16.56% of the portfolio (though existing Healthcare holdings ALGN and INCY mature within 4.9–5.9 days). Solvency and binary-event risks are low ($16.2B net cash mfn.seRegeneron Reports Third Quarter 2026 Financial and ...X-dag kvartalsutdelning REGN 0.94. 2026-10-30, -, Kvartalsrapport 2026 ... Regeneron's website at www.regeneron.com. Upon registration ...Visit original website ↗; no scheduled earnings/FDA events through Nov 27).
  • Explicit Thesis Breakers:
    1. Sustained loss of intraday regular-session VWAP ($934.47–$934.59) followed by a breakdown below SMA20 ($901.91) and the authored structural stop at $888.00.
    2. Material analyst downgrades citing Livsayis REMS/pricing friction or accelerating EYLEA biosimilar pressure.
    3. Broad macro liquidation following the Nov 25 PCE/GDP cluster that invalidates REGN's low-beta defensive bid.

Investment Recommendation

Action: Buy REGN (Regeneron Pharmaceuticals, Inc.) as a Momentum (Defensive Post-FDA Approval) position for the 7-calendar-day horizon (2026-11-19 12:20:01 EST to 2026-11-26 12:20:01 EST, with first liquid regular-session exit on Friday, 2026-11-27 09:30–13:00 EST nyseHolidays & Trading HoursICE NYSE LOGIN Listings Trading Market Data Insights About Trading at NYSE / Holidays & Trading Hours Holidays & Trading Hours All NYSE markets observe U.S. holidays as listed below for 2026, 2027, and 2028. Trading Days Trading Hours Holiday 2026 2027 2028 New Year’s Day Thursday, January 1 Friday, January 1 —* Martin Luther King, Jr. Day Monday, January 19 Monday, January 18 Monday, January 17 Washington's…Visit original website ↗).

Execution Parameter Authoritative Value Notes & Provenance
Frozen Research Entry (entry_price) $937.94 Observed 2026-11-19 13:02:00 EST finance.yahooYahoo Finance: Regeneron Pharmaceuticals, Inc.Yahoo Finance quote pageVisit original website ↗ (Fresh publication quote: $936.031 at 13:17:00 EST finance.yahooYahoo Finance: Regeneron Pharmaceuticals, Inc.Yahoo Finance quote pageVisit original website ↗)
Authored Structural Stop (stop_loss_price) $888.00 (-5.32%) 1.25x ATR14, below SMA20 ($901.91) & VWAP20 ($912.96) (decider level)
Conditional Expected Stop Exit (stop_exit_price) $874.00 (-6.82%) Decider estimate modeling 90-min MA60 delay & gap risk before 0.15% friction
First Resistance (first_resistance_price) $965.48 (+2.94%) Path diagnostic only (Nov 17 session high finance.yahooYahoo Finance: Regeneron Pharmaceuticals, Inc.Yahoo Finance quote pageVisit original website ↗)
7-Day Reference Target (target_price / T1) $988.00 (+5.34%) Decider 7-day reference target just below $991.73 52-week high
Actual Full-Position Profit Barrier (1.8x T1 %) $1,028.05 (+9.61%) Policy full-position take-profit barrier (1.8 × 5.337%)
Decider Exit Probabilities (Uncalibrated) 18% / 18% / 64% Barrier / Stop / Time Exit (+1.61% time-exit return); early exits hold cash
Execution Friction & Stress Uncertainty 0.15% / 3.35% 0.10% adverse slippage + 0.05% holiday buffer; 3.35% covers adverse stress

Execution & Stop-Loss Policy (authored_stop_ma60_confirm90_spot_mom15_hard15_confirm10_tp1p8_v2):

  • Profit-Taking: T1 ($988.00, +5.34%) is the decider's 7-day reference target, while the automated full-position profit barrier sits at 1.8x T1's percentage return ($1,028.05, +9.61%). Any early exit holds cash through maturity.
  • Authored Stop Confirmation: The $888.00 (-5.32%) stop does not guarantee an exact fill at $888.00. It requires the trailing 60-minute average price to remain at or below $888.00 for a 90-minute confirmation window, with spot price still at or below $888.00 and a nonpositive 15-minute price change (if 15-minute momentum is missing, exit is deferred; intraday recovery checks preserve the timer until the trailing 60-minute average recovers above $888.00).
  • Hard Loss Backstop & Slippage: An emergency 15% hard-loss backstop triggers after a 10-minute confirmation. Overnight/holiday gaps and confirmation delays can produce materially worse fills than $888.00 (modeled at $874.00 conditional expected stop exit), and all exits incur at least 0.10% adverse slippage (0.15% total modeled friction).
  • Limitations: All exit probabilities, terminal SPY weights, and stop-exit estimates are uncalibrated decider estimates rather than source-reported facts. Note that REGN trades ex-dividend ($0.94/share) tomorrow, 2026-11-20 finance.yahooRegeneron Pharmaceuticals, Inc. (REGN) Stock Historical Prices & Data - Yahoo FinanceSkip to navigation Skip to main content Skip to right column Home News Finance Sports More Sign in My Portfolio Markets Anthropic IPO News Research & Tools Personal Finance Watch Crypto AI Network AlphaSpace Get Finance Plus US Markets S&P 500 7,218.98 -104.65 -1.43% Dow 30 49,331.06 -867.11 -1.73% Nasdaq 24,068.04 -361.84 -1.48% Russell 2000 2,679.52 -34.79 -1.28% 10-Yr Bond 5.06 -0.00 -0.04% VIX 26.87 +2.31 +9.42%…Visit original website ↗.

Financial Snapshot

As of Nov 19, 2026 Afternoon

Pr. $936.03
Market Cap 96.84B
P/E Ratio 20.69
52W High $991.73
52W Low $591.52
Volume 292.4K
Sector Healthcare
Dividend Yield 0.40%
Beta 0.10

References

Disclaimer: This is not financial advice. All investments carry risk. Please do your own research and consult with a financial advisor before making investment decisions.